News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Mohamedtaki A. Tejani: A crash course on Bayesian design at ASCOGI25
Jan 27, 2025, 09:39

Mohamedtaki A. Tejani: A crash course on Bayesian design at ASCOGI25

Mohamedtaki A. Tejani, Hematology/Oncology Specialist at Advent Health Medical Group, shared a post on X:

“Namrata Vijayvergia gives us a crash course on Bayesian design as she does the difficult task of giving an engaging discussion on 2 negative studies GI25.”
Mohamedtaki A. Tejani: A crash course on Bayesian design at ASCOGI25

cancer Mohamedtaki A Tejani Namrata Vijayvergia OncoDaily Oncology
Special Coverage
Drugs
Aug 8, 2025, 07:08
Adagrasib (Krazati) Updates 2025: Uses in Cancer, Side Effects, Dosages, Expectations, and More
Career
Aug 8, 2025, 06:20
Joseph Contessa Selected as the Chair of Radiation Oncology at Rutgers Cancer Institute
Dialogues
Aug 8, 2025, 06:16
Accelerating Cancer Drug Development with AI: Interview with Dr. Jen-Tang (JT) Lu from Vysioneer
Blog
Aug 8, 2025, 06:08
Better-Targeted Therapies for Patients with Acute Myeloid Leukemia - IU Simon Comprehensive Cancer Center
Blog
Aug 8, 2025, 05:59
The Silver Jubilee of the Townsville to Cairns Bike Ride: Raising Funds for Childhood Cancer - Children's Cancer Institute
Insight
Aug 8, 2025, 05:47
FASCO 2025: 97 Voices, One Mission: Part 2
Science
Aug 8, 2025, 05:44
Yan Leyfman: Turning Paradoxical Biology Into Precision Immunotherapy Opportunities
Science
Aug 8, 2025, 05:01
Arndt Vogel: ESMO-MCBS 2.0 Scorecards for Hepatocellular Carcinoma
Oncolibrary
Aug 8, 2025, 03:13
CAR T-Cell Therapy vs iNKT Cell Therapy: The Future of Engineered Immune Cells in Cancer Treatment
Oncolibrary
Aug 8, 2025, 03:09
Immunotherapy for Cancer Success Rate: What Patients Need to Know in 2025
Oncolibrary
Aug 8, 2025, 01:07
10-Minute Immunotherapy Infusion: Safe, Efficient Delivery of Nivolumab and Pembrolizumab
Societies
Aug 7, 2025, 23:50
Because Every Patient Matters: Promoting Diversity in Cancer Support - MASCC